| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/S10165-010-0325-3 |
| P8608 | Fatcat ID | release_vfoxry646zhkhetllsfm4xjrxm |
| P932 | PMC publication ID | 3036807 |
| P698 | PubMed publication ID | 20574648 |
| P50 | author | Désirée van der Heijde | Q47262835 |
| P2093 | author name string | Hideki Yoshikawa | |
| Kazuhiko Yamamoto | |||
| Tsutomu Takeuchi | |||
| Patrick Garnero | |||
| Nobuyuki Miyasaka | |||
| Norihiro Nishimoto | |||
| Shinichi Kawai | |||
| Jun Hashimoto | |||
| P2860 | cites work | Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 |
| Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study | Q30980061 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 | ||
| Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab | Q35954629 | ||
| Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial | Q42950968 | ||
| Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis | Q44003346 | ||
| A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs | Q47772154 | ||
| Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. | Q50779374 | ||
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 | ||
| How to read radiographs according to the Sharp/van der Heijde method | Q73386051 | ||
| Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers | Q81377123 | ||
| Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis | Q81629373 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| tocilizumab | Q425154 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 10-15 | |
| P577 | publication date | 2010-06-24 | |
| P1433 | published in | Modern Rheumatology | Q15752709 |
| P1476 | title | Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad | |
| P478 | volume | 21 |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q27687777 | Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities |
| Q26852235 | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis |
| Q30243911 | Biologic therapies and bone loss in rheumatoid arthritis. |
| Q58774487 | Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications |
| Q33563068 | Bone remodelling markers in rheumatoid arthritis. |
| Q85963569 | Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series |
| Q53633328 | Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. |
| Q30882161 | Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study |
| Q53789625 | Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. |
| Q34092425 | Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study |
| Q43675571 | Guidelines for the drug treatment of rheumatoid arthritis |
| Q30439206 | IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia |
| Q55058284 | IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. |
| Q39122209 | Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases |
| Q60916226 | Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma |
| Q41901416 | Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model |
| Q38164315 | Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis |
| Q36550827 | Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab |
| Q33811774 | Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data |
| Q37250988 | Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. |
| Q53546741 | Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis. |
| Q85736797 | Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis |
| Q35982627 | Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab |
| Q46671185 | Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. |
| Q37358242 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis |
| Q38125456 | Treat-to-target: a tailored treatment approach to rheumatoid arthritis |
Search more.